Breakpoints cover image

#69 – IDWeek 2022 Recap: Practice Changing Publications – Midnights Edition

Breakpoints

00:00

Long Acting Injectables for HIB

The second trial they talked about for treatment was more of a real world setting trial done in San Francisco and this was done in 51 patients in an urban public health HIB clinic. Patients there to be enrolled couldn't have had rope hivering mutations or more than one in a race inhibitor mutation. 24 patients at enrollment were already virologically suppressed and they remain suppressed and undetectable for the whole study period. 15 patients started with detectable by Remia which I think has been an area that people are unsure about with these long acting injectables. 12 of these patients got to an undetectable viral load. Two of those patients have never previously been suppressed ever in more than 10 years of

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app